Trial Profile

A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 07 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sacituzumab tirumotecan (Primary) ; Dexamethasone; Docetaxel; Laxatives; Paclitaxel; Paracetamol; Vinflunine
Indications Carcinoma; Urogenital cancer
Focus Registrational; Therapeutic Use
Acronyms TroFuse-031
Sponsors Merck Sharp & Dohme

21 Apr 2026 Planned initiation date changed from 15 Apr 2026 to 30 Apr 2026.
07 Apr 2026 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com